Ribon Therapeutics, Cambridge, Massachusetts, USA.
Curr Opin Allergy Clin Immunol. 2023 Oct 1;23(5):370-375. doi: 10.1097/ACI.0000000000000940. Epub 2023 Jul 31.
The purpose of this literature review was to review the latest use of biologics in the management of anaphylaxis. The methodology was to highlight both the nonbiologic management of anaphylaxis and the biologic management and how they can be used in conjunction with each other.
As the phenotypes and endotypes of anaphylaxis are better portrayed, it furthers our understanding of the mechanisms of anaphylaxis. New applications of existing biologics to the prevention of anaphylaxis are described.
Anaphylaxis is a potentially life-threatening acute hypersensitivity reaction affecting up to 16.8% of the U.S. population. Acute management entails swift identification, removal of the causative agent, and the prevention of cardiovascular collapse, firstly with epinephrine. Adjunctive treatments such as antihistamines work to prevent anaphylaxis from recurring. Biologic management of anaphylaxis involves the use of large-molecule drugs such as monoclonal antibodies. Omalizumab, an IgG1 monoclonal antibody targeting unbound IgE, is the most prevalent and widely studied biologic in the prevention of anaphylaxis. Other monoclonal antibodies in development or approved for other indications, such as ligelizumab, quilizumab, MEDI4212, and dupilumab, may also have potential for preventing anaphylaxis through various mechanisms.
本文献综述的目的是回顾生物制剂在过敏反应管理中的最新应用。方法是重点介绍过敏反应的非生物管理和生物管理，以及它们如何相互结合使用。
随着过敏反应表型和内型的更好描述，我们对过敏反应的机制有了更深入的了解。描述了现有生物制剂在预防过敏反应中的新应用。
过敏反应是一种潜在的危及生命的急性过敏反应，影响了美国多达 16.8%的人口。急性管理需要迅速识别、去除致病因素，并预防心血管衰竭，首先使用肾上腺素。辅助治疗，如抗组胺药，可预防过敏反应再次发生。过敏反应的生物治疗涉及使用大分子药物，如单克隆抗体。奥马珠单抗是一种针对未结合 IgE 的 IgG1 单克隆抗体，是预防过敏反应最常见和广泛研究的生物制剂。其他正在开发或批准用于其他适应症的单克隆抗体，如利昔单抗、 quilizumab、MEDI4212 和 dupilumab，也可能通过各种机制预防过敏反应。
